Mergers and acquisitions – Page 9
-
BusinessShire bets big on rare diseases
$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations
-
Business
ChemChina buys German machinery maker
Plastics and rubber equipment manufacturer KraussMaffei Group will retain German headquarters after €1bn deal
-
Business
ThermoFisher will buy Affymetrix to expand genetic testing
Deal boosts Thermo’s position in growing genomics field as well as adding antibodies and assay technology
-
Business
GSK’s ViiV to buy HIV drugs from BMS
Deal hands over Bristol-Myers Squibb’s entire HIV pipeline as the company looks to quit virology research
-
Business
AstraZeneca to buy Acerta for blood cancer drug
Deal will strengthen AstraZeneca’s immunotherapy offering
-
-
Business
BioAtla and Pfizer to collaborate on antibody research
Two-way agreement to share technology and royalties on new cancer drugs
-
-
BusinessDow and DuPont mega-merger heralds break-up of giants
New firm will split itself in speciality, agrichemical and materials businesses with R&D taking a hit from cost savings
-
Business
Heptares takes on new partners for drug discovery
Firm set to receive over $1bn from research partnerships
-
Business
Perrigo nabs US rights to AZ Crohn’s drug
Irish generics maker evades Mylan takeover bid and expands gastroenterology portfolio
-
Business
Dow ditches older herbicides
Gowan will acquire Dow’s entire dinitroaniline herbicide portfolio
-
BusinessMerger creates new gases giant
Air Liquide will buy Airgas in a $13 billion deal to become the world’s biggest industrial gases supplier
-
BusinessPfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
Business
AstraZeneca to buy ZS Pharma for ion-balance drugs
$2.7 billion deal anticipates regulatory success for drug candidate under review
-
Business
Samsung to sell chemicals businesses to Lotte
Korean conglomerate Lotte will pay £1.7 billion for stake in Samsung’s chemicals businesses
-
Business
Dow backs off of Kuwaiti joint ventures
EQUATE will acquire MEGlobal as part of Dow’s restructuring of its Kuwaiti joint ventures
-
Business
Shire to buy rare disease specialist Dyax
Deal includes an already-approved drug for angioedema and an experimental antibody treatment
-
Business
Bristol-Myers Squibb to buy Cardioxyl for heart drug
Deal worth up to $2bn gives BMS full rights to Phase II clinical candidate
-
Business
BMS agrees $1.7bn immuno-oncology collaboration
Deal strengthens cancer antibody alliance with Five Prime Therapeutics